Purpose of review
This update discusses novel aspects on genetics, diagnosis, and treatments of atypical parkinsonism published over the past 2 years.

Recent findings
A genome-wide association study identified new genetic risk factors for progressive supranuclear palsy and new genetic conditions presenting with atypical parkinsonism have been described. The clinical criteria for diagnosis of corticobasal degeneration have been revised, and for progressive supranuclear palsy are under revision. Novel molecular techniques to identify possible biomarkers, as in other neurodegenerative disorders, have started being studied on atypical parkinsonian conditions, and although preliminary results seem promising, further studies are urgently warranted. Therapeutic trials based on disease-specific targets have shown no clinical improvement.

Summary
The knowledge obtained recently on atypical parkinsonian conditions points out the major deficits in this field. With the expanding phenotypical spectrum of atypical parkinsonian conditions, the early identification of patients has become difficult. The inability of conventional methods to identify these disorders earlier and better than clinicians, and the recent failure of promising therapeutic compounds, highlight the fact that the lack of biomarkers is probably the greatest limitation for developing treatments for these disorders. Thus, current and future research in this direction will be crucial.

Keywords
atypical parkinsonian disorders, cerebrospinal fluid biomarkers, diagnostic, genetics, therapy

INTRODUCTION
Atypical parkinsonian conditions comprise mostly progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), multiple system atrophy (MSA), and dementia with Lewy bodies (DLB). Apart from these sporadic neurodegenerative disorders, atypical parkinsonism has also been described in a variety of other heredodegenerative conditions such as frontotemporal dementia (FTD), Alzheimer’s disease, and Perry syndrome. With the recent advent in genetics, these disorders are constantly increasing [1].

Despite decades of research, the cause and pathophysiology of atypical parkinsonian disorders are still unknown. Moreover, the early differential diagnosis of patients with atypical parkinsonism, which would be important for clinical (e.g., prognosis and treatment) and research purposes, is poor. Therapeutic options are still limited. However, in recent years, there have been some new insights into atypical parkinsonian conditions regarding genetic, diagnostic, and treatment aspects, which will be discussed in this review.

UPDATE ON GENETICS
Recently, the first genome-wide association study (GWAS) has been performed in PSP to identify genes that modify risk for this primary tauopathy. Apart from confirming two independent variants in MAPT affecting risk for PSP, this study identified three significant novel signals associated with PSP risk, which may give some insight into the

*Correspondence to Dr Maria Stamelou, Sobell Department of Motor Neurosciences and Movement Disorders, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK. Tel: +44 203 108 0023; e-mail: m.stamelou@ucl.ac.uk

Curr Opin Neurol 2013, 26:401–405
DOI:10.1097/WCO.0b013e3283632da6
This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
A GWAS study in PSP has identified new loci possibly related to the disease pathophysiology, while in MSA a GWAS is underway.

New clinical criteria are proposed for CBD and are under revision for PSP.

New possible candidates are currently being evaluated as possible biomarkers for atypical parkinsonism condition.

Recent therapeutic trials in PSP have failed to show any clinical benefit, and this indicates the urgent need for identification of biomarkers in these disorders.

This study needs to be further confirmed by independent studies.

In recent years, there has been tremendous research on genetic forms of frontotemporal lobar degeneration (FTLD), which has identified genes that may present with atypical parkinsonism, and in some cases also mimicking PSP, CBD, or MSA [1]. For example, microtubule-associated protein tau (MAPT) and progranulin (PGRN) gene mutations [tau and TAR DNA-binding protein-43 (TDP-43) pathology, respectively], both inherited in a dominant pattern, are known to cause atypical parkinsonism [1]. However, a major recent breakthrough in the genetics of FTLD and amyotrophic lateral sclerosis has been the identification of hexanucleotide expansions in chromosome 9 open reading frame 72 (C9ORF72) gene (TDP-43 pathology), which classically cause FTD–amyotrophic lateral sclerosis overlap syndromes [5,6]. However, 35% of these patients may also have atypical parkinsonism, and cases with slowness of vertical saccades, parkinsonism, frontal dementia, and abnormal DaTSCANs, mimicking PSP but also corticobasal syndrome (CBS), have been reported [5,6,7–10]. One study has screened a large population of patients with atypical parkinsonism and found this mutation to be rare in apparently sporadic patients with PSP, CBS, and MSA [11]. In a further study, 3.2% of patients with a PSP phenotype carried the mutation [12]. Apart from the genes causing FTLD, further genetic disorders presenting with atypical parkinsonism have been increasingly recognized [1,13].

The following section summarizes advances in clinical, imaging, and nonimaging diagnostics and new possible candidates that may serve as biomarkers for these disorders.

Clinical criteria
Pathology remains the gold standard for definite diagnosis for PSP, CBD, MSA, and DLB. For clinical diagnosis, diagnostic criteria have been widely used; however, these have never been verified prospectively and there is a need for independent clinicopathological confirmation. Recently, a clinicopathological evaluation of the NINDS-SPSP (National Institute of Neurological Disorders and Stroke and Society for Progressive Supranuclear Palsy) [14] vs. NNIPPS (the Neuroprotection and Natural History in Parkinson Plus Syndromes) [15] criteria was conducted on 98 PSP patients and demonstrated that the NINDS-SPSP ‘probable’ criteria yielded shorter time to diagnosis,
slightly higher specificity and positive predictive value, and similar sensitivity, compared with the NNIIPPS criteria, whereas a combination of NINDS-SPSP possible and probable criteria yielded the highest sensitivity. Thus, it is suggested that the NINDS-SPSP probable criteria might be preferred for recruitment of patients for clinical trials, whereas for routine clinical care, a combination of NINDS possible and probable criteria might be preferred [16*]. However, there is currently a Movement Disorders Society Task Force undertaking revision of the PSP clinical criteria.

Also, new diagnostic criteria for CBD have been proposed. In this study, clinical diagnoses were identified for 267 nonoverlapping pathologically confirmed CBD cases from published reports and brain banks [17*]. Four CBD phenotypes emerged: CBS, frontal behavioral-spatial syndrome, nonfluent/agrammatic variant of primary progressive aphasia, and PSP syndrome, which has also been confirmed by another independent study [18*]. Clinical CBD phenotypes and features were combined to create two sets of criteria: more specific clinical research criteria for probable CBD and broader criteria for possible CBD that are more inclusive but have a higher chance to detect other tau-based diseases [17*]. However, future validation and refinement of the proposed criteria are needed.

**Structural and functional imaging**

Several abnormalities in MRI have been proposed in the past as possible candidates to differentiate between atypical parkinsonian syndromes [19]. However, their sensitivity and specificity had not been confirmed in pathologically proven cases. MR images from 48 neuropathologically confirmed cases, including PSP (n = 22), MSA (n = 13), Parkinson’s disease (n = 7), CBD (n = 6), and controls (n = 9) were assessed retrospectively in one study and it was found that the clinical diagnosis was more sensitive in PSP (90.9% in PSP compared with 72.7% in MSA) and the radiological diagnosis more sensitive in MSA (61.5% in PSP compared with 76.9% in MSA) [20]. The radiological diagnosis was more specific than the clinical diagnosis in both PSP and MSA, and radiologically no case of MSA was classified as PSP or vice versa. The most clinically useful abnormalities seen in PSP were signs of midbrain atrophy (86.4%), superior cerebellar peduncle atrophy, and frontal and parietal cortical atrophy. The ‘morning glory flower sign’ and the ‘humming bird sign’ were very specific but with a low sensitivity (50 and 68.4%, respectively). In MSA, only 50% had putaminal atrophy and 25% the hyperintense putaminal rim. Middle cerebellar peduncle hyperintensity was found in 50.0% of the MSA patients, and the hot cross bun sign in 58.3% [20]. These findings suggest that better and novel MRI techniques are needed to improve sensitivity and to be able to serve as specific biomarkers for monitoring disease progression.

Functional imaging has been used in the differential diagnosis of parkinsonism. One recent study showed that sensitivity/specificity of [18F]FDG-PET (F-18 fluorodeoxyglucose positron emission tomography) in identifying atypical parkinsonian subgroups was 77/97% for MSA, 74/95% for PSP, and 75/92% for CBD (clinically diagnosed patients) [21]. In another study, 136 parkinsonian patients underwent [18F] FDG-PET and the results were compared to a 2-year follow-up of clinical assessment. Concordance of visual evaluation of [18F] FDG-PET with clinical diagnosis was achieved in 80% MSA, 76.6% PSP, and 100% CBS patients. Blinded computer assessment using statistical parametric mapping was concordant with the clinical diagnosis in 80% MSA, 93.3% PSP, and 100% CBS patients [22], suggesting its possible usefulness in the differential diagnosis of these disorders.

**Novel diagnostic approaches**

Research has focused in recent years on possible novel molecular biomarkers for atypical parkinsonian conditions [23,24]. Studies on specific proteins in cerebrospinal fluid (CSF) have shown some preliminary but often contradictory results: CSF alpha-synuclein levels in MSA have been reported to be decreased compared with controls (but not with Parkinson’s disease patients) [24,25**], but normal in another study [26]. In PSP and CBD, CSF alpha-synuclein levels were not significantly different compared with controls, but levels in PSP were higher than in Parkinson’s disease [25**]. CSF total tau and phosphorylated tau levels were not significantly different in PSP and CBD compared with controls in a large study on patients with dementia [27*], but was increased in MSA and CBD compared with Parkinson’s disease with no significant change in PSP in another study [25**]. Aβ42 did not differ significantly between controls and Parkinson’s disease, MSA, PSP, and CBD [25**].

Further studies have investigated a combination of proteins. Mollenhauer et al. [24] found that CSF mean alpha-synuclein levels and not total tau or Aβ42 levels differentiated Parkinson’s disease and MSA from neurological controls (70% sensitivity, 53% specificity), whereas a combination of alpha-synuclein, tau protein, and age discriminated between synucleinopathies and neurological controls and Alzheimer’s disease [area under the curve (AUC) 0.908]. Moreover, a combination of
alpha-synuclein and phosphorylated tau/total tau could differentiate Parkinson’s disease from MSA with a sensitivity of 90% and a specificity of 71% in another study [28]. Neurofilament light chain (NFL) as a biomarker of axonal degeneration was increased in atypical parkinsonian syndromes and differentiated from Parkinson’s disease (AUC of 0.93), which has been confirmed in another study [29]. The Flt3 ligand, a cytokine that acts as a neurotrophic and antiapoptotic factor in CNS, could alone differentiate between Parkinson’s disease and MSA with a sensitivity of 99% and a specificity of 95% [28]. All these promising approaches need large prospective cohorts of early cases to be confirmed and validated.

Other approaches include the ‘-omics’ (genomics, transcriptomics, proteomics, metabolomics), but less research has been done in atypical parkinsonian disorders in this direction [30]. One study applied a proteomic profiling strategy for parkinsonian diseases using mass spectrometry analysis for magnetic-bead-based enrichment of CSF peptides/proteins and subsequent multivariate statistical analysis on 37 Parkinson’s disease patients, 32 MSA patients, and 26 patients with other neurological diseases as controls. Receiver operating characteristics proved that the peak of m/z 6250 was the most important to differentiate MSA from Parkinson’s disease, especially in the early stages of the disease; however, these results await confirmation from further studies [31]. Undoubtedly, these methods are promising for the future identification of biomarkers, which are urgently needed in these disorders.

UPDATE ON TREATMENTS

Although there are still no treatments available for the sporadic atypical parkinsonian conditions, important efforts have been done in recent years, which, even if not proven effective clinically, will certainly guide further research. A randomized, placebo-controlled clinical trial to assess the effects of treatment with the monoamine oxidase-B inhibitor rasagiline (1 mg/day) for 48 weeks in 174 patients with possible or probable MSA-Parkinsonism type, in 39 sites in 12 countries, found no significant difference in progression in the total Unified Multiple System Atrophy Rating Scale (UMSARS) score between the verum and placebo groups [32]. A single-arm, single-center, open-label pilot trial evaluated monthly infusions of 0.4 g/kg intravenous immunoglobulin for 6 months in seven patients as an anti-inflammatory approach, and found significantly increased SBP and improved UMSARS part I (activities of daily living) and II (motor functions); verification in a controlled study was proposed [33]. Lee et al. [34] compared 30-50 intraarterial or intravenous injections of autologous mesenchymal stem cells (MSCs, 4 x 107/injection) vs. placebo in 33 patients with probable MSA-cerebellar type and suggested that the MSC group had a smaller increase in total and part II UMSARS scores from baseline throughout a 360-day follow-up period; as the mechanism of action of this intervention remains unclear, a careful experimental and clinical re-evaluation of these findings should be considered [34].

In regard to PSP, a multinational phase 2/3 randomized, double-blind, placebo-controlled trial enrolled 313 participants, to be treated with 30 mg davunetide or placebo twice daily for 52 weeks at 47 sites, and found no significant effect on the co-primary outcome measures, the Progressive Supranuclear Palsy Rating Scale (PSPRS) and the Schwab and England Activities of Daily Living (SEADL) (Press release December 18, 2012 by Allon Therapeutics, www.allontherapeutics.com). An open label pilot trial of lithium, an inhibitor of glycogen synthase kinase-3 (GSK-3), in individuals with PSP or CBD (ClinicalTrials.gov Identifier NCT00703677) recruited 17 patients and was stopped prematurely because the majority of participants did not tolerate the study drug. A multinational, phase II, double-blind, placebo-controlled trial enrolled 142 patients with PSP, who were treated orally with tideglusib (600 or 800 mg p.d.), also a GSK-3 inhibitor, or placebo for 1 year. There were no significant differences between the high dose, low dose, and either dose groups vs. the placebo group in the primary clinical outcome measures. A subset of 37 patients underwent baseline and 52-week MRI; this substudy demonstrated significantly reduced global brain atrophy in tideglusib-treated patients [35]. The effect of GSK-3 inhibition in PSP thus warrants further investigation.

CONCLUSION

The knowledge obtained recently on atypical parkinsonian conditions points out clearly what are the major deficits in this field, which, compared to other neurodegenerative diseases, lacks major advances in terms of early diagnosis and treatments. With the expanding phenotypical spectrum of atypical parkinsonian conditions, the early identification of patients has become difficult; thus, new clinical criteria are being currently revised. The inability of conventional methods such as MRI to identify these disorders earlier and better than clinicians, and the recent failure of promising therapeutic compounds based on rational therapeutic hypotheses [36] highlight the fact that the lack of
biomarkers is probably the greatest limitation for developing treatments for these disorders. Thus, current and future research in this direction will be crucial.

Acknowledgements
G.H. is funded by the Deutsche Forschungsgemeinschaft (HO 2402/6-1).

Conflicts of interest
There are no conflicts of interest.

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:
- of special interest
- of outstanding interest

Additional references related to this topic can also be found in the Current World Literature section in this issue (p. 458).

1. Stammler M, Quinn N, Bhatia K. 'Atypical' parkinsonism: new genetic disorders presenting with features of PSP, MSA or CBD. Mov Disord 2013. [Epub ahead of print]
2. Hoglinger GU, Melhem NM, Dickson DW, et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet 2011; 43:699–705.
3. Ahmed Z, As Y, Saier A, et al. The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol Appl Neurobiol 2012; 38:4–24.
4. The Multiple-System Atrophy Research Collaboration. Mutations in COQ2 in multiple system atrophy. N Engl J Med 2013. [Epub ahead of print]
5. Majounie E, Renton AE, Mol K, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 2012; 11:293–300.

This is an important study on the frequency and phenotypes of patients with C9orf72 hexanucleotide repeat expansions.

6. Mahoney CJ, Beck J, Rohrer JD, et al. Frontotemporal dementia with the C9orf72 hexanucleotide repeat expansion: clinical, neuropsychological and neuropathological features. Brain 2012; 135:736–750.

This is an important study highlighting both clinical and pathological features in patients with this newly identified gene, also presenting the clinical characteristics of patients with atypical parkinsonism.

7. Boeve BF, Boylan KB, Grad-Raford NR, et al. Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain 2012; 135:765–783.
8. Hodges J. Familial frontotemporal dementia and amyotrophic lateral sclerosis associated with the C9ORF72 hexanucleotide repeat. Brain 2012; 135:652–655.
9. O'Dowd S, Curtin D, Waite AJ, et al. C9ORF72 expansion in amyotrophic lateral sclerosis/frontotemporal dementia also causes parkinsonism. Mov Disord 2012; 27:1072–1074.
10. Lindquist S, Duno M, Batbay M, et al. Corticobasal and ataxia syndromes widen the spectrum of C9ORF72 hexanucleotide expansion disease. Clin Genet 2013; 85:279–283.

This study has investigated the frequency of C9orf72 in patients with sporadic atypical parkinsonian disorders.

11. Le Ber I, Condroyer C, et al. C9orf72 repeat expansions are a rare genetic cause of parkinsonism. Brain 2013; 136:385–391.

This study investigated the frequency of C9orf72 in patients with sporadic atypical parkinsonian disorders.

12. Le Ber I, Camuzat A, Guillet-Noel L, et al. C9ORF72 repeat expansions in the frontotemporal dementia spectrum of diseases: a flow-chart for genetic testing. J Alzheimers Dis 2013; 34:485–499.

This study provides an evaluation of the frequency of C9ORF72 expansions in a large series of well characterized patients with different diseases of the FTD spectrum as well as PSP and CBDs. It also provides evidence that C9orf72 mutations may cause a classical PSP phenotype at least for the first years of the disease.

13. Rubio-Agusti I, Kovacic M, Edwards MJ, et al. Atypical parkinsonism and cerebrotendinous xanthomatosis: report of a family with corticobasal syndrome and a literature review. Mov Disord 2012; 27:1769–1774.

Atypical parkinsonism: an update
Stammler and Hoeglinger

14. Litvan I, Mangone CA, McKee A, et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olzewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry 1996; 60:615–620.
15. Bensimon G, Ludolph A, Agid Y, et al. Rituxolite treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 2009; 132:156–171.
16. Respondide G, Roebber S, Kretzschmar H, et al. Accuracy of the National Institute for Neurological Disorders and Stroke/Society for Progressive Supranuclear Palsy and Neuroprotection and Natural History in Parkinson Plus Syndromes criteria for the diagnosis of progressive supranuclear palsy. Mov Disord 2013; 28:504–509.

This is the first study of this kind, comparing two different sets of clinical criteria using a large clinicopathological population.

17. Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013; 80:496–503.

These are the new proposed clinical diagnostic criteria for CBD.

18. Stammler M, Alonso-Canovas A, Bhatia KP. Dysostia in corticobasal degeneration: a review of the literature on 404 pathologically proven cases. Mov Disord 2012; 27:896–702.

This review described the clinical features and phenotypes of all published pathlogy-proven CBD patients.

19. Stammler M, Krake S, Oertel WH, Hoglinger GU. Magnetic resonance imaging in progressive supranuclear palsy. J Neurol 2011; 258:549–558.
20. Massey LA, Micall C, Paviour DC, et al. Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Brain 2012; 27:1754–1762.
21. Helwig S, Amtage F, Kreth A, et al. [123I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology 2012; 79:1314–1322.
22. Tripati M, Dhawan V, Peng S, et al. Differential diagnosis of parkinsonian syndromes using F-18 fluorodeoxyglucose positron emission tomography. J Neurol Neurosurg Psychiatry 2013; 85:483–492.
23. Luk C, Compta Y, Magdalino N, et al. Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. J Neurochem 2012; 113:396–405.
24. Mollenhauer B, Locascio JJ, Schultz-Schaeffer W, et al. alpha-Synuclein and tau concentrations in cerebrospinal fluid patients with parkinsonism: a cohort study. Lancet Neurol 2011; 10:230–240.
25. Hall S, Ohrfelt A, Constantinescu R, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012; 69:1445–1452.

This comprehensive study found that the level of NFL alone may differentiate Parkinson’s disease from atypical parkinsonian disorders.

26. Tateno F, Sakakibara R, Kawasaki T, et al. Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease. Alzheimer Dis Assoc Disord 2012; 26:213–216.
27. Schonemann BS, Reiss PK, Verrey NA, et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 2012; 78:47–54.

This study determined how amyloid (p)42 (Alz42), total tau (t-tau), and phosphorylated tau (p-tau) levels in CSF behave in a large cohort of patients with different types of dementia including atypical parkinsonian syndromes.

28. Olsson M, Bradner J, Hancoc AM, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011; 69:570–580.
29. Bech S, Hjermand LE, Salvesen L, et al. Amyloid-related biomarkers and axonal damage proteins in parkinsonism syndromes. Parkinsonism Relat Disord 2012; 18:69–72.
30. Constantinescu R, Mondello S. Cerebrospinal fluid biomarker candidates for parkinsonian disorders. Front Neurol 2012; 3:187.

This is an excellent review on the current state of the research in several possible biomarker candidates for neurodegenerative diseases.

31. Ishigami N, Tokuda T, Negawa M, et al. Cerebrospinal fluid proteomic patterns discriminate Parkinson’s disease and multiple system atrophy. Mov Disord 2012; 27:851–857.
32. Poewe W, Barone P, Giardi N, et al. A randomized, placebo-controlled clinical trial to assess the effects of rasagiline in patients with multiple system atrophy of the parkinsonian subtype. Mov Disord 2012; 27 (Suppl 1):1182.
33. Novak P, Williams A, Ravin P, et al. Treatment of multiple system atrophy using immunoglobulin. BMC Neurol 2012; 12:131.
34. Lee PH, Lee JE, Kim HS, et al. A randomized trial of mesenchymal stem cells in multiple system atrophy. Ann Neurol 2012; 72:32–40.
35. Hoglinger GU, Huppertz HJ, Wagenpfel FS, et al. Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial, Alzheimer’s Association International Conference; 2012; Vancouver, British Columbia, Canada, Proposal number: 34102.
36. Stammler M, de Silva R, Araujo-Carmon O, et al. Rational therapeutic approaches to progressive supranuclear palsy. Brain 2010; 133:1578–1590.